An <i>MGRN1</i>-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

A highly significant difference in survival rates was also observed when we grouped all patients into two categories: patients with a priori favorable stages (TNM-F, stages 0–IIIB, median OS 1419 days), or patients with unfavorable prognostic (TNM-NF, stages IIIC–IV, median OS 590 days, HR = 3.3) ( Figure 1 b,c), confirming the association of lower TNM at diagnosis and longer OS.

also in 132,142 other papers